This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
We will be welcoming you to our Ed Forum: ASH 2020 Comes to You on Thursday, February 4th, register here. Although there were some great surprises, ASH 2020 brought us data that was more evolutionary than revolutionary. Much of the research presented was focused on improving outcomes by studying, not only drug sequencing or combinations, but how to best manage therapy, including limited-duration treatments guided by uMRD status. We are grateful to the medical researchers who have dedicated their professional lives to vanquishing the complex challenges of CLL. The ASH Annual Meeting is our window into their world.
Ed Forum: ASH 2020 Comes to You
ASH 2020 Comes to You is taking place on Feb. 4th at 10:00 AM PT, 11:00 AM MT, 12:00 PM CT, and 1:00 PM ET. Highlights will include Dr. Anthony Mato explaining the excitement around LOXO-305, updates from the inform CLL Registry which validates CLL Society’s Test Before Treat™ campaign, and a one pill triple combination therapy that is currently in clinical trials targeting Richter’s Transformation. Dr. William Wierda will explain the TRANSCEND CAR-T study using Liso-cel (JCAR017) in combination with ibrutinib, and present updated data from the MRD Cohort of the CAPTIVATE Study. Dr. Brian Koffman will round out the presentations with his Top Picks of those studies not covered by Drs. Wierda and Mato, including one demonstrating impressive results using fresh CAR-T cells in patients with Richter’s Transformation. Don’t miss it! Register here.
Ed Forum Questions
Already registered, but just thought of a question? We’ll still take it! Send your questions to Support@cllsociety.org with the subject line “ASH 2020 Ed Forum” before Feb. 3rd. See you there on Feb. 4th!
In this interview from ASH 2020, Dr. William Wierda presents updated data from the MRD Cohort of the CAPTIVATE Study, which combined ibrutinib and venetoclax in previously untreated CLL patients in a fixed-duration regimen to improve outcomes. After achieving uMRD, patients were randomized into one of two groups, one arm receiving ibrutinib, the other arm receiving no further therapy. Which did better? Learn more here.
In this interview at iwCLL 2019, Dr. Nicole Lamanna’s interview strongly affirms CLL Society’s Test Before Treat™ campaign. Learn more here.
Regulatory News: Calquence Update
In a gutsy and much anticipated first head-to-head trial looking at two BTK inhibitors in previously treated high-risk CLL patients, there was no statistically significant difference in efficacy found between acalabrutinib and ibrutinib. Learn more here.
Vaccine Prioritization Letter
Please help move cancer patients to the front of the COVID-19 vaccination line in your state. CLL Society has contacted the health departments in all 50 states + DC (accurate as of this posting), so that you can find out immediately through our nifty link whether your state has already prioritized cancer patients to receive the vaccine or not. If not, we are asking you to take a few minutes to Click, fill, send our letter asking your state’s health department to do so now! The life you save may be your own. Thank you.
BMS has extended their COVID-19 financial relief program to cover medications for those who have lost health insurance due to loss of employment. Learn more here.
MRD and Limited Duration (LD) Survey
Help the CLL Society find out what our CLL patients and their caregivers already know and still yearn to learn about MRD (Minimal Residual Disease) testing and Limited Duration Therapies. Your input + our future programming = Smarter Patients Getting Smarter Care! Please complete our MRD & Limited Duration Therapy Survey. Thank you!
Quick links to great help from the CLL Society
- New to CLL? Neil Kay leads the way!
- CLL Support Groups, here is THE BIG MAP
- Test Before Treat™(download here)
- CLL Society’s Official Statement on Vaccines (updated 1/4/2021)(download here)
- Normal Lab Values (download here)
- Glossary of Terms (download here)
We are celebrating 10 Years of covering ASH (and all the other major hematology conferences) to bring you the most important, breaking CLL research news in patient-friendly terms. Support the ongoing work of the CLL Society. Please donate today. Thank you!
CLL Society is the only CLL-specific, physician-curated public charity dedicated to meeting the unmet needs of CLL patients and their caregivers which holds the GuideStar Platinum Seal of Transparency.
We are all in this together.
Co-Founder & Communications Director
CLL Society Support Group Meetings Coming Up!
CLL Society Support Group meetings have moved to a virtual platform for most locations due to the threat of coronavirus. Support group members will receive an invitation to register for the meeting from the support group facilitator. If you are new to the group, please contact the RSVP email for the Support Group in your region. Once it is safe again, we will resume in-person meetings.
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.